New immune therapy tested for Tough-to-Treat cancers
NCT ID NCT04844073
Summary
This early-stage study tested a new drug called TAK-186 in adults with advanced cancers of the head & neck, lung, or colon that could not be removed by surgery. The main goal was to find a safe dose and understand the drug's side effects. Researchers also looked for early signs that the drug could help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul Teugbyeolsi, 5505, South Korea
-
Avera Cancer Institute at Sioux Falls
Heidelberg, Victoria, 3004, Australia
-
Chris O'Brien Lifehouse Hospital
Sydney, New South Wales, 2050, Australia
-
Columbia University Medical Center -161 Fort Washington
New York, New York, 10032, United States
-
Fred Hutchinson Cancer Research Center - 1100 Fairview Ave N
Seattle, Washington, 98109, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Indiana University
Indianapolis, Indiana, 43202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030-4000, United States
-
Mary Crowley Cancer Research Centers Medical City - SCRI - PPDS
Dallas, Texas, 75230, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Monash University - Australian Centre for Blood Diseases (ACBD)
Clayton, Victoria, 3168, Australia
-
Northwestern University
Chicago, Illinois, 60611-2814, United States
-
Novant Health Cancer Institute - Elizabeth Head and Neck
Charlotte, North Carolina, 28204-3282, United States
-
Paula Fox Melanoma and Cancer Centre
Melbourne, Victoria, 3004, Australia
-
Samsung Medical Center
Seoul, 6351, South Korea
-
Sanford Cancer Center
Sioux Falls, South Dakota, 57105-1521, United States
-
Sarah Cannon Research Institute UK - SCRI - PPDS
London, Middlesex, W1G 6AD, United Kingdom
-
Scientia Clinical Research Limited
Randwick, New South Wales, 2031, Australia
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 3080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, Seodaemun-Gu, 3722, South Korea
-
Southern Oncology Clinical Research
Bedford Park, South Australia, 5042, Australia
-
The Christie - PPDS
Manchester, M20 4BX, United Kingdom
-
UC San Diego Moores Cancer Center
San Diego, California, 92037, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Colorado - Anschutz Medical Campus - PPDS
Aurora, Colorado, 80045-2517, United States
-
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, 55414-2959, United States
-
Yale University
New Haven, Connecticut, 06510-3206, United States
Conditions
Explore the condition pages connected to this study.